Trial Profile
A Phase II Trial of Carboplatin, Bevacizumab and Pemetrexed in Advanced Non-Small Cell Lung Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Apr 2017
Price :
$35
*
At a glance
- Drugs Pemetrexed (Primary) ; Bevacizumab; Carboplatin
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 31 Mar 2017 Status changed from active, no longer recruiting to completed.
- 03 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jul 2017.
- 08 Jul 2016 Planned End Date changed from 1 Dec 2016 to 1 Jul 2017.